Back to Journals » Psoriasis: Targets and Therapy » Volume 2

Plaque psoriasis in children and adolescents – the role of etanercept

Authors Ricceri F, Tripo L, Pescitelli L, Prignano F

Received 12 April 2012

Accepted for publication 7 May 2012

Published 11 June 2012 Volume 2012:2 Pages 25—28

DOI https://doi.org/10.2147/PTT.S26032

Review by Single anonymous peer review

Peer reviewer comments 2


Federica Ricceri, Lara Tripo, Leonardo Pescitelli, Francesca Prignano

Division of Clinical, Preventive and Oncology Dermatology, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy

Background: Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. In Europe, etanercept has recently been approved for children aged 6 years and over. Data from a well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the onset of therapy. The treatment is generally well tolerated; mild injection site reactions are the most common adverse events reported in the literature. Published data of etanercept use in children show promising results, but further clinical studies are necessary to confirm its long-term efficacy and safety.

Keywords:
pediatric psoriasis, anti-TNF-α, etanercept

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]